Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME Study of 14C-Labeled Tozadenant in Healthy Males
NCT02240290Phase 1Completed
- Sponsor
- Biotie Therapies
- Start
- Sep 2013
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tozadenant in Parkinson's disease (PD), sponsored by Biotie Therapies. Primary endpoints: Composite of total radioactivity concentration and cumulative percentage of radioactive dose at Day 14 and Composite pharmacokinetic parameters of the total radioactivity at Day 14. Started Sep 2013; status: completed.
02
Drugs
tozadenant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02240290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240290.